SlideShare a Scribd company logo
Kidney Donor Profile Index (KDPI)
Evolving idea or false solace
Goutham Kumar, MD
Consultant
Abdominal Transplant Surgery
Manipal Hospitals
 Introduction to the concept of KDPI
 Calculation of KDPI
 Parameters considered in KDPI and their significance
 Intended uses
 KDPI in Kidney Allocation
 Limitations of KDPI
Synopsis
Introduction to KDPI
Transplant decision
The quality of organ at present is objectively determined by
Expanded Criteria Donor (ECD)
Age >60
Age >50 with at least two of the following conditions:
I.Hypertension
II.Serum creatinine > 1.5 mg/dl
III.Cerebrovascular accident
Issues:
Donor age – main criteria in assessment of quality of an organ
Low predictive value because of binary (yes/no) characteristics
ECD stigma – High discard rate (44% in 2010) possibly due to ECD stigma
Why KDPI over ECD?
Why KDPI?
KDPI illuminates the fact that not all ECDs are alike
-Some ECD kidneys have reasonably good estimated quality
-Some SCD kidneys actually have lower estimated quality than some ECDs
That’s Why KDPI
KDPI
Proposed in order to improve risk stratification of kidneys so that clinicians
can more easily determine if a kidney offer is right for his or her candidate.
The “kidney donor profile index” (KDPI) is a score that informs clinicians about
the potential longevity of a kidney relative to other kidneys.
The calculation of KDPI includes 10 donor factors and is a more precise
measure of donor quality as compared to ECD/SCD dichotomy (only 4 donor
characteristics)
continuous PERCENTILE “score” instead of a binary (yes/no) indicator
Calculation of KDPI
 Calculation of KDRI (Kidney Donor Risk Index)
 Mapping of KDRI to KDPI - Relative risk scale to cumulative percentile scale
Steps involved in the calculation of KDPI
• University of Michigan - Ann Arbor
• Multivariable Cox proportional hazards regression model - to estimate the
association between the donor/recipient/transplant factors and graft survival
( Stratified by recipient age, diabetes status and transplant center)
• 69440 - first time, kidney-only, adult transplant
• 10 donor factors and 4 transplant factors were identified with significant
hazard ratio - to model KDRI
• In calculation of KDPI, Donor only KDRI (KDRI-RAO) is used as transplant
factors/recipient characteristics are different for each case.
170cm
80kg
Correlation between KDRI and KDPI
Summary of KDPI calculation
Donor factor
Reference donor Donor 1 Donor 2 Donor 3 Donor 4 Donor 5 Donor 6 Donor 7 Donor 8 Donor 9 Donor 10
Age (yr) 40 30 40 40 40 40 40 40 40 40 40
Race Non-Black Non-Black Black Non-Black Non-Black Non-Black Non-Black Non-Black Non-Black Non-Black Non-Black
Hypertensive No No No No No Yes No No No No No
Diabetic No No No No No No Yes No No No No
Serum creatinine 1 1 1 1 1 1 1 1.5 1 1 1
Cause of death Non-CVA Non-CVA Non-CVA Non-CVA Non-CVA Non-CVA Non-CVA Non-CVA CVA Non-CVA Non-CVA
Height(cm) 170 170 170 160 170 170 170 170 170 170 170
Weight(kg) 80 80 80 80 70 80 80 80 80 80 80
HCV status Negative Negative Negative Negative Negative Negative Negative Negative Negative positive Negative
DCD
No No No No No No No No No No Yes
KDRI-median 0.82 0.72 0.98 0.86 0.85 0.93 0.93 0.91 0.89 1.04 0.93
KDPI 31 18 48 35 34 43 43 41 39 54 44
How do the Individual donor characteristic affects KDPI?
Rules of thumb
 Ideal donor according to KDPI – Age 19, 80kg, 6’3’’, non-CVA, DBD with no
comorbidities
 Age increase of 1yr increases KDPI by 1%, every 10yr increase by 12%
 Black donor - Higher KDPI by 17%, literally means a 23 yo black donor would be
similar to 40 yo non-black donor
 Height – Every 2cm increase in height reduces 1% in KDPI, and vice versa.
 Weight – Every 10kg decrease in weight from reference donor weight increases 4%
in KDPI. No change in increase in weight
 Hypertension & Diabetes – 12% higher KDPI each
 Serum creatinine – 10% Higher KDPI if serum creatinine is increased from 1 to
1.5, then 1% for every 1mg/dL increase in Cr
 HCV positivity increases KDPI by 23%
 DCD donor increases KDPI by 13%
Can we use KDRI/KDPI for other organs?
 For Liver and pancreas - Separate organ risk indices LDRI and PDRI respectively are developed,
But does KDRI correlate well with LDRI/PDRI with similar discriminatory power.
 On the other hand, KDRI was also shown to have very modest discriminatory power (c=0.54) for
heart transplant outcomes and very little association with lung transplant outcomes (c=0.52)
Stewart DE et al. Is the Kidney Donor Risk Index (KDRI) a Useful Predictor of Graft
Survival for Non-Renal Organs? ATC Abstract #464.
Intended uses of KDPI
KDPI as an analytical tool on DonorNet® - some
intended uses
1. Evaluation of deceased donor kidney
2. Differentiate - Lower versus higher quality ECD kidneys
3. Determination of need to implant both the kidneys or not
4. May help OPO predict which donors/organs may be more
less difficult to place.
5. In future, a part of allocation algorithm
Evaluation of deceased donor kidney
Evaluation of deceased donor kidney
Correlation between KDPI and Graft survival
Differentiate - Lower versus higher quality ECD kidneys
KDPI in organ allocation
Problems with Current allocation system
 High discard rates
 Access variability due to geography and biology
 Longevity Mismatch in graft/patient survival
 waiting time has become the primary driver of kidney allocation
 Histocompatibility components have diminished
 This overreliance led to a system that does not accomplish any goal other than
transplanting the candidate waiting the longest
 Fails to acknowledge different needs for different candidates (e.g., speed over
quality)
Increasing need and high discard rates for cadaveric kidneys
 Optimal utilization of procured cadaveric kidneys – Reduce discard rates
 Promote graft survival for those at highest risk of re-transplant.
 Minimize loss of potential graft function through better longevity matching
 Improve efficiency and utilization by providing better information about kidney
offers
 Provide comprehensive data to guide transplant decision making
 Reduce differences in access variability due to geography and biology
Ideal allocation system
 Candidate age,
 Length of time on dialysis,
 Any prior organ transplant, and
 Diabetes status.
Estimated Post-Transplant Survival (EPTS)
Proposed Allocation system - Model
New system forecasted to result in: 8,380 additional life years gained annually
Expected Outcomes
New proposed system – Higher transplant rates in younger population
Expected Outcomes
Limitations of KDPI
Limitations - KDPI
1. Is statistics and data analysis for KDPI sound enough?
The use of risk factors as prognostic tool for the purpose of prospective
individual risk stratification often yields disappointing results.
Ware JH. The limitations of risk factors as prognostic tools. N Engl J Med 2006;355: 2615-7.
 The predictive power of the KDPI is only moderate (c=0.62), but when
highest and lowest quintiles were compared then c-statistic improved
to 0.78. Better in extremes and ‘muddy’ in middle
 Though there is a definite difference between the kidneys with KDPI of
10 and 90, there may not be any difference in KDPI of 40 and 60.
Different KDPI means different interpretation
Biopsy and trauma not included in KDPI
KDPI does not include all donor factors potentially associated with kidney
graft outcomes.
Biopsy
No information about damage, trauma, or abnormalities in kidneys
KDPI was developed using graft outcomes from strictly adult transplant recipients; It can
only be used in pediatric donors but not recipients.
.
May reduce live-donor kidney transplants?
 Potential reduction in live donor kidney transplants in younger patients (53%
in age 18-34, 41% in 35-49)
 Overdependence on less available live donors for older patients (33% in 50-
64, 28% in 65 & older
.
Hippen BE, Thistlethwaite JR Jr, Ross LF. Risk, prognosis, and unintended consequences in
kidney allocation N Engl J Med. 2011
KDPI based allocation system – disadvantageous for
certain groups
 Patients with short term diabetes with similar outcomes as non-diabetics
 Elderly recipients
Conclusions in this topic are still a
matter of debate.
Thank you

More Related Content

What's hot

SUSTAINED LOW EFFICIENCY DAILY DIALYSIS (SLEDD)
SUSTAINED LOW EFFICIENCY DAILY DIALYSIS (SLEDD)SUSTAINED LOW EFFICIENCY DAILY DIALYSIS (SLEDD)
SUSTAINED LOW EFFICIENCY DAILY DIALYSIS (SLEDD)
د. أنور الموسوي
 
Care Bundles in Sepsis
Care Bundles in SepsisCare Bundles in Sepsis
Care Bundles in Sepsis
NIICS
 
Perioperative Cardiovascular Risk assessment
Perioperative Cardiovascular Risk assessmentPerioperative Cardiovascular Risk assessment
Perioperative Cardiovascular Risk assessment
Nizam Uddin
 
Rotem - A Cook's Tour
Rotem - A Cook's TourRotem - A Cook's Tour
Rotem - A Cook's Tour
SCGH ED CME
 
Management of organ donor following brain death 2016
Management of organ donor following brain death  2016Management of organ donor following brain death  2016
Management of organ donor following brain death 2016
intentdoc
 
Complications & troubleshooting in continuous renal replacement therapy
Complications & troubleshooting in continuous renal replacement therapyComplications & troubleshooting in continuous renal replacement therapy
Complications & troubleshooting in continuous renal replacement therapy
mansoor masjedi
 
RRT
RRTRRT
Journal Club: Residual renal function
Journal Club: Residual renal functionJournal Club: Residual renal function
Journal Club: Residual renal function
Hofstra Northwell School of Medicine
 
Updated vascular topic cvc
Updated vascular topic cvc Updated vascular topic cvc
Updated vascular topic cvc
Mai Parachy
 
Patient Blood Management
Patient Blood ManagementPatient Blood Management
Patient Blood Management
Mathurange Krishnapillai
 
Renal Replacement therapy in the ICU
Renal Replacement therapy in the ICU Renal Replacement therapy in the ICU
Renal Replacement therapy in the ICU
Syed Hussain
 
Adequacy hd
Adequacy hdAdequacy hd
Adequacy hd
FarragBahbah
 
Renal replacement therapy
Renal replacement therapyRenal replacement therapy
Renal replacement therapy
aratimohan
 
Maintenance of a potential brain dead donor
Maintenance of a potential brain dead donorMaintenance of a potential brain dead donor
Maintenance of a potential brain dead donor
Dr. Prashant Kumar
 
Adequacy of Hemodialysis
Adequacy of HemodialysisAdequacy of Hemodialysis
Adequacy of Hemodialysis
MNDU net
 
Massive transfusion protocol
Massive transfusion protocolMassive transfusion protocol
Massive transfusion protocol
akshaya tomar
 
Contrast Induced Nephropathy
Contrast Induced NephropathyContrast Induced Nephropathy
Contrast Induced Nephropathy
Aris Tsalouchos
 
Patient blood management(1)
Patient blood management(1)Patient blood management(1)
Patient blood management(1)
Figo Khan
 
Dialysis in aki
Dialysis in akiDialysis in aki
Dialysis in aki
FarragBahbah
 
DHCA
DHCA DHCA
DHCA
Manu Jacob
 

What's hot (20)

SUSTAINED LOW EFFICIENCY DAILY DIALYSIS (SLEDD)
SUSTAINED LOW EFFICIENCY DAILY DIALYSIS (SLEDD)SUSTAINED LOW EFFICIENCY DAILY DIALYSIS (SLEDD)
SUSTAINED LOW EFFICIENCY DAILY DIALYSIS (SLEDD)
 
Care Bundles in Sepsis
Care Bundles in SepsisCare Bundles in Sepsis
Care Bundles in Sepsis
 
Perioperative Cardiovascular Risk assessment
Perioperative Cardiovascular Risk assessmentPerioperative Cardiovascular Risk assessment
Perioperative Cardiovascular Risk assessment
 
Rotem - A Cook's Tour
Rotem - A Cook's TourRotem - A Cook's Tour
Rotem - A Cook's Tour
 
Management of organ donor following brain death 2016
Management of organ donor following brain death  2016Management of organ donor following brain death  2016
Management of organ donor following brain death 2016
 
Complications & troubleshooting in continuous renal replacement therapy
Complications & troubleshooting in continuous renal replacement therapyComplications & troubleshooting in continuous renal replacement therapy
Complications & troubleshooting in continuous renal replacement therapy
 
RRT
RRTRRT
RRT
 
Journal Club: Residual renal function
Journal Club: Residual renal functionJournal Club: Residual renal function
Journal Club: Residual renal function
 
Updated vascular topic cvc
Updated vascular topic cvc Updated vascular topic cvc
Updated vascular topic cvc
 
Patient Blood Management
Patient Blood ManagementPatient Blood Management
Patient Blood Management
 
Renal Replacement therapy in the ICU
Renal Replacement therapy in the ICU Renal Replacement therapy in the ICU
Renal Replacement therapy in the ICU
 
Adequacy hd
Adequacy hdAdequacy hd
Adequacy hd
 
Renal replacement therapy
Renal replacement therapyRenal replacement therapy
Renal replacement therapy
 
Maintenance of a potential brain dead donor
Maintenance of a potential brain dead donorMaintenance of a potential brain dead donor
Maintenance of a potential brain dead donor
 
Adequacy of Hemodialysis
Adequacy of HemodialysisAdequacy of Hemodialysis
Adequacy of Hemodialysis
 
Massive transfusion protocol
Massive transfusion protocolMassive transfusion protocol
Massive transfusion protocol
 
Contrast Induced Nephropathy
Contrast Induced NephropathyContrast Induced Nephropathy
Contrast Induced Nephropathy
 
Patient blood management(1)
Patient blood management(1)Patient blood management(1)
Patient blood management(1)
 
Dialysis in aki
Dialysis in akiDialysis in aki
Dialysis in aki
 
DHCA
DHCA DHCA
DHCA
 

Viewers also liked

Critères de Financement FAFIEC 2017
Critères de Financement FAFIEC 2017Critères de Financement FAFIEC 2017
Critères de Financement FAFIEC 2017
Business Class Language Solutions
 
Word of The Lord, 2017: Your Cup will Overflow
Word of The Lord, 2017: Your Cup will OverflowWord of The Lord, 2017: Your Cup will Overflow
Word of The Lord, 2017: Your Cup will Overflow
All Peoples Church and World Outreach
 
2017 catálogo ciclo 1
2017 catálogo ciclo 12017 catálogo ciclo 1
2017 catálogo ciclo 1
Maurício Miotti
 
Capacity_Statement_January_2014_2
Capacity_Statement_January_2014_2Capacity_Statement_January_2014_2
Capacity_Statement_January_2014_2
Claus Otto Nielsen
 
CV of Celia Ong 2016
CV of Celia Ong 2016CV of Celia Ong 2016
CV of Celia Ong 2016
Celia Ong
 
AE3000_CorProfile
AE3000_CorProfileAE3000_CorProfile
AE3000_CorProfile
Om Prakash
 
ENG_Prosthesis Next re-Generation Start Up_Business Model_2014
ENG_Prosthesis Next re-Generation Start Up_Business Model_2014ENG_Prosthesis Next re-Generation Start Up_Business Model_2014
ENG_Prosthesis Next re-Generation Start Up_Business Model_2014
Luca Borgio
 
Engineer your day to day
Engineer your day to dayEngineer your day to day
Engineer your day to day
Alex Standiford
 
Common Symptoms Of Transmission Problems
Common Symptoms Of Transmission ProblemsCommon Symptoms Of Transmission Problems
Common Symptoms Of Transmission Problems
Orion Automotive Service
 
Computación
ComputaciónComputación
Computación
Belén Araujo
 
1 sample16c136 psycho-social-assessment-and-intervention-plan
1 sample16c136 psycho-social-assessment-and-intervention-plan1 sample16c136 psycho-social-assessment-and-intervention-plan
1 sample16c136 psycho-social-assessment-and-intervention-plan
Mary Jones
 
Hendricks - Proposta de Comunicação 360º (Estratégia e execução)
Hendricks - Proposta de Comunicação 360º (Estratégia e execução)Hendricks - Proposta de Comunicação 360º (Estratégia e execução)
Hendricks - Proposta de Comunicação 360º (Estratégia e execução)
João Almeida
 
Hola
HolaHola

Viewers also liked (13)

Critères de Financement FAFIEC 2017
Critères de Financement FAFIEC 2017Critères de Financement FAFIEC 2017
Critères de Financement FAFIEC 2017
 
Word of The Lord, 2017: Your Cup will Overflow
Word of The Lord, 2017: Your Cup will OverflowWord of The Lord, 2017: Your Cup will Overflow
Word of The Lord, 2017: Your Cup will Overflow
 
2017 catálogo ciclo 1
2017 catálogo ciclo 12017 catálogo ciclo 1
2017 catálogo ciclo 1
 
Capacity_Statement_January_2014_2
Capacity_Statement_January_2014_2Capacity_Statement_January_2014_2
Capacity_Statement_January_2014_2
 
CV of Celia Ong 2016
CV of Celia Ong 2016CV of Celia Ong 2016
CV of Celia Ong 2016
 
AE3000_CorProfile
AE3000_CorProfileAE3000_CorProfile
AE3000_CorProfile
 
ENG_Prosthesis Next re-Generation Start Up_Business Model_2014
ENG_Prosthesis Next re-Generation Start Up_Business Model_2014ENG_Prosthesis Next re-Generation Start Up_Business Model_2014
ENG_Prosthesis Next re-Generation Start Up_Business Model_2014
 
Engineer your day to day
Engineer your day to dayEngineer your day to day
Engineer your day to day
 
Common Symptoms Of Transmission Problems
Common Symptoms Of Transmission ProblemsCommon Symptoms Of Transmission Problems
Common Symptoms Of Transmission Problems
 
Computación
ComputaciónComputación
Computación
 
1 sample16c136 psycho-social-assessment-and-intervention-plan
1 sample16c136 psycho-social-assessment-and-intervention-plan1 sample16c136 psycho-social-assessment-and-intervention-plan
1 sample16c136 psycho-social-assessment-and-intervention-plan
 
Hendricks - Proposta de Comunicação 360º (Estratégia e execução)
Hendricks - Proposta de Comunicação 360º (Estratégia e execução)Hendricks - Proposta de Comunicação 360º (Estratégia e execução)
Hendricks - Proposta de Comunicação 360º (Estratégia e execução)
 
Hola
HolaHola
Hola
 

Similar to Kidney Donor Profile Index (KDPI)

KSN-2019_KDIGO-KSN_03_Jung-Pyo-Lee.pdf
KSN-2019_KDIGO-KSN_03_Jung-Pyo-Lee.pdfKSN-2019_KDIGO-KSN_03_Jung-Pyo-Lee.pdf
KSN-2019_KDIGO-KSN_03_Jung-Pyo-Lee.pdf
DrmadouhNada
 
Myths in Nephrology 1
Myths in Nephrology 1Myths in Nephrology 1
Myths in Nephrology 1
Meguid Nahas
 
Scoring systems in liver disease
Scoring systems in liver diseaseScoring systems in liver disease
Scoring systems in liver disease
Karthik Ponnappan T
 
Role of endoscopy in choledocholithiasis
Role of endoscopy in choledocholithiasis Role of endoscopy in choledocholithiasis
Role of endoscopy in choledocholithiasis
Thorsang Chayovan
 
Bernstein Oct 29 2008 Defining Ckd And Risk Factors
Bernstein Oct 29 2008 Defining Ckd And Risk FactorsBernstein Oct 29 2008 Defining Ckd And Risk Factors
Bernstein Oct 29 2008 Defining Ckd And Risk Factors
guest6940925
 
Donor hepatectomy
Donor hepatectomyDonor hepatectomy
Donor hepatectomy
Apollo Hospitals
 
Dialytic support-of-aki-dep-2017
Dialytic support-of-aki-dep-2017Dialytic support-of-aki-dep-2017
Dialytic support-of-aki-dep-2017
FarragBahbah
 
What Their Poo Can Tell You: How FIT (iFOBT) Fits Your Colorectal Cancer Algo...
What Their Poo Can Tell You: How FIT (iFOBT) Fits Your Colorectal Cancer Algo...What Their Poo Can Tell You: How FIT (iFOBT) Fits Your Colorectal Cancer Algo...
What Their Poo Can Tell You: How FIT (iFOBT) Fits Your Colorectal Cancer Algo...
Patricia Raymond
 
Living related organ transplantation
Living related organ transplantationLiving related organ transplantation
Living related organ transplantation
Sunil Kumar
 
Revolutionizing Renal Care With Predictive Analytics for CKD
Revolutionizing Renal Care With Predictive Analytics for CKDRevolutionizing Renal Care With Predictive Analytics for CKD
Revolutionizing Renal Care With Predictive Analytics for CKD
Viewics
 
Perspectives in Peritoneal Dialysis
Perspectives in Peritoneal DialysisPerspectives in Peritoneal Dialysis
Perspectives in Peritoneal Dialysis
Richard McCrory
 
Dyslipidemia 2016
Dyslipidemia 2016Dyslipidemia 2016
CKD or C-K-D; Cardio-Kidney-Disease
CKD or C-K-D; Cardio-Kidney-DiseaseCKD or C-K-D; Cardio-Kidney-Disease
CKD or C-K-D; Cardio-Kidney-Disease
Meguid Nahas
 
Selection and maintenance of a cadaver donor for liver transplantation
Selection and maintenance of a cadaver donor for liver transplantationSelection and maintenance of a cadaver donor for liver transplantation
Selection and maintenance of a cadaver donor for liver transplantation
Apollo Hospitals
 
SCN cardiac leads national meeting July 2014
SCN cardiac leads national meeting July 2014SCN cardiac leads national meeting July 2014
SCN cardiac leads national meeting July 2014
NHS Improving Quality
 
Marginal and extended criteria donors
Marginal and extended criteria donorsMarginal and extended criteria donors
Marginal and extended criteria donors
Dr. Rohit Saini
 
Pcp in a box module 1
Pcp in a box   module 1Pcp in a box   module 1
Pcp in a box module 1
MohibaAgha
 
injuria renal 4.pptx
injuria renal 4.pptxinjuria renal 4.pptx
injuria renal 4.pptx
MartyMcfly25
 
1. Chronic Disease Avoidance and Personal Longevity - Ultimate Summary.pptx
1. Chronic Disease Avoidance and Personal Longevity - Ultimate Summary.pptx1. Chronic Disease Avoidance and Personal Longevity - Ultimate Summary.pptx
1. Chronic Disease Avoidance and Personal Longevity - Ultimate Summary.pptx
Ivor Cummins
 
CHRONIC KIDNEY DISEASES
CHRONIC KIDNEY DISEASESCHRONIC KIDNEY DISEASES
CHRONIC KIDNEY DISEASES
Zayd Rafid
 

Similar to Kidney Donor Profile Index (KDPI) (20)

KSN-2019_KDIGO-KSN_03_Jung-Pyo-Lee.pdf
KSN-2019_KDIGO-KSN_03_Jung-Pyo-Lee.pdfKSN-2019_KDIGO-KSN_03_Jung-Pyo-Lee.pdf
KSN-2019_KDIGO-KSN_03_Jung-Pyo-Lee.pdf
 
Myths in Nephrology 1
Myths in Nephrology 1Myths in Nephrology 1
Myths in Nephrology 1
 
Scoring systems in liver disease
Scoring systems in liver diseaseScoring systems in liver disease
Scoring systems in liver disease
 
Role of endoscopy in choledocholithiasis
Role of endoscopy in choledocholithiasis Role of endoscopy in choledocholithiasis
Role of endoscopy in choledocholithiasis
 
Bernstein Oct 29 2008 Defining Ckd And Risk Factors
Bernstein Oct 29 2008 Defining Ckd And Risk FactorsBernstein Oct 29 2008 Defining Ckd And Risk Factors
Bernstein Oct 29 2008 Defining Ckd And Risk Factors
 
Donor hepatectomy
Donor hepatectomyDonor hepatectomy
Donor hepatectomy
 
Dialytic support-of-aki-dep-2017
Dialytic support-of-aki-dep-2017Dialytic support-of-aki-dep-2017
Dialytic support-of-aki-dep-2017
 
What Their Poo Can Tell You: How FIT (iFOBT) Fits Your Colorectal Cancer Algo...
What Their Poo Can Tell You: How FIT (iFOBT) Fits Your Colorectal Cancer Algo...What Their Poo Can Tell You: How FIT (iFOBT) Fits Your Colorectal Cancer Algo...
What Their Poo Can Tell You: How FIT (iFOBT) Fits Your Colorectal Cancer Algo...
 
Living related organ transplantation
Living related organ transplantationLiving related organ transplantation
Living related organ transplantation
 
Revolutionizing Renal Care With Predictive Analytics for CKD
Revolutionizing Renal Care With Predictive Analytics for CKDRevolutionizing Renal Care With Predictive Analytics for CKD
Revolutionizing Renal Care With Predictive Analytics for CKD
 
Perspectives in Peritoneal Dialysis
Perspectives in Peritoneal DialysisPerspectives in Peritoneal Dialysis
Perspectives in Peritoneal Dialysis
 
Dyslipidemia 2016
Dyslipidemia 2016Dyslipidemia 2016
Dyslipidemia 2016
 
CKD or C-K-D; Cardio-Kidney-Disease
CKD or C-K-D; Cardio-Kidney-DiseaseCKD or C-K-D; Cardio-Kidney-Disease
CKD or C-K-D; Cardio-Kidney-Disease
 
Selection and maintenance of a cadaver donor for liver transplantation
Selection and maintenance of a cadaver donor for liver transplantationSelection and maintenance of a cadaver donor for liver transplantation
Selection and maintenance of a cadaver donor for liver transplantation
 
SCN cardiac leads national meeting July 2014
SCN cardiac leads national meeting July 2014SCN cardiac leads national meeting July 2014
SCN cardiac leads national meeting July 2014
 
Marginal and extended criteria donors
Marginal and extended criteria donorsMarginal and extended criteria donors
Marginal and extended criteria donors
 
Pcp in a box module 1
Pcp in a box   module 1Pcp in a box   module 1
Pcp in a box module 1
 
injuria renal 4.pptx
injuria renal 4.pptxinjuria renal 4.pptx
injuria renal 4.pptx
 
1. Chronic Disease Avoidance and Personal Longevity - Ultimate Summary.pptx
1. Chronic Disease Avoidance and Personal Longevity - Ultimate Summary.pptx1. Chronic Disease Avoidance and Personal Longevity - Ultimate Summary.pptx
1. Chronic Disease Avoidance and Personal Longevity - Ultimate Summary.pptx
 
CHRONIC KIDNEY DISEASES
CHRONIC KIDNEY DISEASESCHRONIC KIDNEY DISEASES
CHRONIC KIDNEY DISEASES
 

Recently uploaded

NARCOTICS- POLICY AND PROCEDURES FOR ITS USE
NARCOTICS- POLICY AND PROCEDURES FOR ITS USENARCOTICS- POLICY AND PROCEDURES FOR ITS USE
NARCOTICS- POLICY AND PROCEDURES FOR ITS USE
Dr. Ahana Haroon
 
share - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptxshare - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptx
Tina Purnat
 
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.GawadHemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
NephroTube - Dr.Gawad
 
Cardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdfCardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdf
shivalingatalekar1
 
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.GawadHemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
NephroTube - Dr.Gawad
 
Cell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune DiseaseCell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune Disease
Health Advances
 
All info about Diabetes and how to control it.
 All info about Diabetes and how to control it. All info about Diabetes and how to control it.
All info about Diabetes and how to control it.
Gokuldas Hospital
 
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptxEar and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptxMuscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
Post-Menstrual Smell- When to Suspect Vaginitis.pptxPost-Menstrual Smell- When to Suspect Vaginitis.pptx
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
FFragrant
 
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdfCHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
rishi2789
 
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
rishi2789
 
Medical Quiz ( Online Quiz for API Meet 2024 ).pdf
Medical Quiz ( Online Quiz for API Meet 2024 ).pdfMedical Quiz ( Online Quiz for API Meet 2024 ).pdf
Medical Quiz ( Online Quiz for API Meet 2024 ).pdf
Jim Jacob Roy
 
Abortion PG Seminar Power point presentation
Abortion PG Seminar Power point presentationAbortion PG Seminar Power point presentation
Abortion PG Seminar Power point presentation
AksshayaRajanbabu
 
Complementary feeding in infant IAP PROTOCOLS
Complementary feeding in infant IAP PROTOCOLSComplementary feeding in infant IAP PROTOCOLS
Complementary feeding in infant IAP PROTOCOLS
chiranthgowda16
 
Physical demands in sports - WCSPT Oslo 2024
Physical demands in sports - WCSPT Oslo 2024Physical demands in sports - WCSPT Oslo 2024
Physical demands in sports - WCSPT Oslo 2024
Torstein Dalen-Lorentsen
 
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
Holistified Wellness
 
Ketone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistryKetone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistry
Dhayanithi C
 
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Oleg Kshivets
 
Osteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdfOsteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdf
Jim Jacob Roy
 

Recently uploaded (20)

NARCOTICS- POLICY AND PROCEDURES FOR ITS USE
NARCOTICS- POLICY AND PROCEDURES FOR ITS USENARCOTICS- POLICY AND PROCEDURES FOR ITS USE
NARCOTICS- POLICY AND PROCEDURES FOR ITS USE
 
share - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptxshare - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptx
 
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.GawadHemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
 
Cardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdfCardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdf
 
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.GawadHemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
 
Cell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune DiseaseCell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune Disease
 
All info about Diabetes and how to control it.
 All info about Diabetes and how to control it. All info about Diabetes and how to control it.
All info about Diabetes and how to control it.
 
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptxEar and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
 
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptxMuscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx
 
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
Post-Menstrual Smell- When to Suspect Vaginitis.pptxPost-Menstrual Smell- When to Suspect Vaginitis.pptx
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
 
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdfCHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
 
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
 
Medical Quiz ( Online Quiz for API Meet 2024 ).pdf
Medical Quiz ( Online Quiz for API Meet 2024 ).pdfMedical Quiz ( Online Quiz for API Meet 2024 ).pdf
Medical Quiz ( Online Quiz for API Meet 2024 ).pdf
 
Abortion PG Seminar Power point presentation
Abortion PG Seminar Power point presentationAbortion PG Seminar Power point presentation
Abortion PG Seminar Power point presentation
 
Complementary feeding in infant IAP PROTOCOLS
Complementary feeding in infant IAP PROTOCOLSComplementary feeding in infant IAP PROTOCOLS
Complementary feeding in infant IAP PROTOCOLS
 
Physical demands in sports - WCSPT Oslo 2024
Physical demands in sports - WCSPT Oslo 2024Physical demands in sports - WCSPT Oslo 2024
Physical demands in sports - WCSPT Oslo 2024
 
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
 
Ketone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistryKetone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistry
 
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
 
Osteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdfOsteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdf
 

Kidney Donor Profile Index (KDPI)

  • 1. Kidney Donor Profile Index (KDPI) Evolving idea or false solace Goutham Kumar, MD Consultant Abdominal Transplant Surgery Manipal Hospitals
  • 2.  Introduction to the concept of KDPI  Calculation of KDPI  Parameters considered in KDPI and their significance  Intended uses  KDPI in Kidney Allocation  Limitations of KDPI Synopsis
  • 5. The quality of organ at present is objectively determined by Expanded Criteria Donor (ECD) Age >60 Age >50 with at least two of the following conditions: I.Hypertension II.Serum creatinine > 1.5 mg/dl III.Cerebrovascular accident Issues: Donor age – main criteria in assessment of quality of an organ Low predictive value because of binary (yes/no) characteristics ECD stigma – High discard rate (44% in 2010) possibly due to ECD stigma Why KDPI over ECD?
  • 6. Why KDPI? KDPI illuminates the fact that not all ECDs are alike -Some ECD kidneys have reasonably good estimated quality -Some SCD kidneys actually have lower estimated quality than some ECDs
  • 7. That’s Why KDPI KDPI Proposed in order to improve risk stratification of kidneys so that clinicians can more easily determine if a kidney offer is right for his or her candidate. The “kidney donor profile index” (KDPI) is a score that informs clinicians about the potential longevity of a kidney relative to other kidneys. The calculation of KDPI includes 10 donor factors and is a more precise measure of donor quality as compared to ECD/SCD dichotomy (only 4 donor characteristics) continuous PERCENTILE “score” instead of a binary (yes/no) indicator
  • 9.  Calculation of KDRI (Kidney Donor Risk Index)  Mapping of KDRI to KDPI - Relative risk scale to cumulative percentile scale Steps involved in the calculation of KDPI
  • 10. • University of Michigan - Ann Arbor • Multivariable Cox proportional hazards regression model - to estimate the association between the donor/recipient/transplant factors and graft survival ( Stratified by recipient age, diabetes status and transplant center) • 69440 - first time, kidney-only, adult transplant • 10 donor factors and 4 transplant factors were identified with significant hazard ratio - to model KDRI • In calculation of KDPI, Donor only KDRI (KDRI-RAO) is used as transplant factors/recipient characteristics are different for each case.
  • 11.
  • 12.
  • 13.
  • 16. Summary of KDPI calculation
  • 17. Donor factor Reference donor Donor 1 Donor 2 Donor 3 Donor 4 Donor 5 Donor 6 Donor 7 Donor 8 Donor 9 Donor 10 Age (yr) 40 30 40 40 40 40 40 40 40 40 40 Race Non-Black Non-Black Black Non-Black Non-Black Non-Black Non-Black Non-Black Non-Black Non-Black Non-Black Hypertensive No No No No No Yes No No No No No Diabetic No No No No No No Yes No No No No Serum creatinine 1 1 1 1 1 1 1 1.5 1 1 1 Cause of death Non-CVA Non-CVA Non-CVA Non-CVA Non-CVA Non-CVA Non-CVA Non-CVA CVA Non-CVA Non-CVA Height(cm) 170 170 170 160 170 170 170 170 170 170 170 Weight(kg) 80 80 80 80 70 80 80 80 80 80 80 HCV status Negative Negative Negative Negative Negative Negative Negative Negative Negative positive Negative DCD No No No No No No No No No No Yes KDRI-median 0.82 0.72 0.98 0.86 0.85 0.93 0.93 0.91 0.89 1.04 0.93 KDPI 31 18 48 35 34 43 43 41 39 54 44 How do the Individual donor characteristic affects KDPI?
  • 18. Rules of thumb  Ideal donor according to KDPI – Age 19, 80kg, 6’3’’, non-CVA, DBD with no comorbidities  Age increase of 1yr increases KDPI by 1%, every 10yr increase by 12%  Black donor - Higher KDPI by 17%, literally means a 23 yo black donor would be similar to 40 yo non-black donor  Height – Every 2cm increase in height reduces 1% in KDPI, and vice versa.  Weight – Every 10kg decrease in weight from reference donor weight increases 4% in KDPI. No change in increase in weight  Hypertension & Diabetes – 12% higher KDPI each  Serum creatinine – 10% Higher KDPI if serum creatinine is increased from 1 to 1.5, then 1% for every 1mg/dL increase in Cr  HCV positivity increases KDPI by 23%  DCD donor increases KDPI by 13%
  • 19. Can we use KDRI/KDPI for other organs?  For Liver and pancreas - Separate organ risk indices LDRI and PDRI respectively are developed, But does KDRI correlate well with LDRI/PDRI with similar discriminatory power.  On the other hand, KDRI was also shown to have very modest discriminatory power (c=0.54) for heart transplant outcomes and very little association with lung transplant outcomes (c=0.52) Stewart DE et al. Is the Kidney Donor Risk Index (KDRI) a Useful Predictor of Graft Survival for Non-Renal Organs? ATC Abstract #464.
  • 21. KDPI as an analytical tool on DonorNet® - some intended uses 1. Evaluation of deceased donor kidney 2. Differentiate - Lower versus higher quality ECD kidneys 3. Determination of need to implant both the kidneys or not 4. May help OPO predict which donors/organs may be more less difficult to place. 5. In future, a part of allocation algorithm
  • 22. Evaluation of deceased donor kidney
  • 23. Evaluation of deceased donor kidney
  • 24. Correlation between KDPI and Graft survival
  • 25. Differentiate - Lower versus higher quality ECD kidneys
  • 26.
  • 27. KDPI in organ allocation
  • 28. Problems with Current allocation system  High discard rates  Access variability due to geography and biology  Longevity Mismatch in graft/patient survival  waiting time has become the primary driver of kidney allocation  Histocompatibility components have diminished  This overreliance led to a system that does not accomplish any goal other than transplanting the candidate waiting the longest  Fails to acknowledge different needs for different candidates (e.g., speed over quality)
  • 29. Increasing need and high discard rates for cadaveric kidneys
  • 30.  Optimal utilization of procured cadaveric kidneys – Reduce discard rates  Promote graft survival for those at highest risk of re-transplant.  Minimize loss of potential graft function through better longevity matching  Improve efficiency and utilization by providing better information about kidney offers  Provide comprehensive data to guide transplant decision making  Reduce differences in access variability due to geography and biology Ideal allocation system
  • 31.  Candidate age,  Length of time on dialysis,  Any prior organ transplant, and  Diabetes status. Estimated Post-Transplant Survival (EPTS)
  • 33.
  • 34.
  • 35. New system forecasted to result in: 8,380 additional life years gained annually Expected Outcomes
  • 36. New proposed system – Higher transplant rates in younger population Expected Outcomes
  • 38. Limitations - KDPI 1. Is statistics and data analysis for KDPI sound enough? The use of risk factors as prognostic tool for the purpose of prospective individual risk stratification often yields disappointing results. Ware JH. The limitations of risk factors as prognostic tools. N Engl J Med 2006;355: 2615-7.
  • 39.  The predictive power of the KDPI is only moderate (c=0.62), but when highest and lowest quintiles were compared then c-statistic improved to 0.78. Better in extremes and ‘muddy’ in middle  Though there is a definite difference between the kidneys with KDPI of 10 and 90, there may not be any difference in KDPI of 40 and 60. Different KDPI means different interpretation
  • 40. Biopsy and trauma not included in KDPI KDPI does not include all donor factors potentially associated with kidney graft outcomes. Biopsy No information about damage, trauma, or abnormalities in kidneys KDPI was developed using graft outcomes from strictly adult transplant recipients; It can only be used in pediatric donors but not recipients. .
  • 41. May reduce live-donor kidney transplants?  Potential reduction in live donor kidney transplants in younger patients (53% in age 18-34, 41% in 35-49)  Overdependence on less available live donors for older patients (33% in 50- 64, 28% in 65 & older . Hippen BE, Thistlethwaite JR Jr, Ross LF. Risk, prognosis, and unintended consequences in kidney allocation N Engl J Med. 2011
  • 42. KDPI based allocation system – disadvantageous for certain groups  Patients with short term diabetes with similar outcomes as non-diabetics  Elderly recipients
  • 43. Conclusions in this topic are still a matter of debate.

Editor's Notes

  1. Additionally, the allocation system has been incrementally changed over the years. Initially, the primary driver of kidney allocation was based on the degree of biological match between the kidney and the recipient. Points were given for HLA-A, B, and DR matching. Over time, points for HLA-A and HLA-B were removed and a candidate’s waiting time became the primary driver of kidney allocation. Unfortunately, the overreliance on waiting time has led to a system that does not accomplish any goal other than transplanting the candidate waiting the longest. This system does not recognize that not everyone has the same ability to survive the wait. These limitations led the Committee to design a system intended to achieve several objectives…
  2. This graph illustrates another reason why revisions to the kidney allocation system are necessary at this time. Over the 30 years since we have been allocating kidneys, the demand for kidney transplant has increased dramatically, from around 10,000 candidates to over 90,000 candidates while the number of kidney transplants has not kept pace with the growing demand. This means that candidates must wait, oftentimes for years to receive a kidney transplant.
  3. <<Review objectives listed>>
  4. The first proposed change is that of Longevity Matching which uses a formula called Estimated Post-transplant Survival (EPTS). Unlike the liver allocation system or the lung allocation system, the current kidney allocation system does not have a candidate classification based risk of death while on the waiting list or estimated post-transplant survival. Incorporating a metric like estimated post-transplant survival would allow for better matching of candidates and donated grafts so that individuals with very long estimated post transplant survival do not receive kidneys with very short survival (necessitating a second or third transplant from an already limited donor pool) and vice versa. Four medical factors about the transplant candidate are used to calculate the Estimated Post-Transplant Survival (EPTS) score: Age History of diabetes Length of time on dialysis History of a prior kidney transplant These factors are also used in a clinical formula. A percentage score estimates how long a candidate is expected to benefit from a functioning kidney when compared to the experience of other recipients over a recent time. A low EPTS percentage indicates likely longer-term survival, and a high percentage indicates shorter likely benefit. An EPTS of 20 percent, for example, suggests that if the candidate is transplanted, he or she would likely survive longer than 80 percent of other recipients. The use of EPTS would not change how the majority of kidney candidates get priority for kidneys – only those expected to need and benefit from a transplant the very longest.
  5. Before we begin, it’s important to see where we’re going. The changes that I am about to describe result in a gain in life years for transplant recipients, as well as improved access for candidates who currently face difficulty receiving a transplant while not disrupting the current geographic distribution of kidneys.